XPO1 and acute myeloid leukemia: 2.3. Pharmacologic Inhibition of XPO1 via Selinexor is HSA Synergistic with FLT3 Inhibition by Either Midostaurin or Gilteritinib in FLT3-ITD AML Cell Lines and Primary Patient Samples